122 related articles for article (PubMed ID: 9840728)
1. Effect of Cremophor EL on the pharmacokinetics, antitumor activity and toxicity of doxorubicin in mice.
Badary OA; Al-Shabanah OA; Al-Gharably NM; Elmazar MM
Anticancer Drugs; 1998 Oct; 9(9):809-15. PubMed ID: 9840728
[TBL] [Abstract][Full Text] [Related]
2. Differential alteration of cisplatin cytotoxicity and myelotoxicity by the paclitaxel vehicle cremophor EL.
Badary OA; Abdel-Naim AB; Khalifa AE; Hamada FM
Naunyn Schmiedebergs Arch Pharmacol; 2000 Mar; 361(3):339-44. PubMed ID: 10731049
[TBL] [Abstract][Full Text] [Related]
3. Thymoquinone protects against doxorubicin-induced cardiotoxicity without compromising its antitumor activity.
al-Shabanah OA; Badary OA; Nagi MN; al-Gharably NM; al-Rikabi AC; al-Bekairi AM
J Exp Clin Cancer Res; 1998 Jun; 17(2):193-8. PubMed ID: 9700580
[TBL] [Abstract][Full Text] [Related]
4. Safety, pharmacokinetics and biodistribution studies of a beta-galactoside prodrug of doxorubicin for improvement of tumor selective chemotherapy.
Devalapally H; Rajan KS; Akkinepally RR; Devarakonda RK
Drug Dev Ind Pharm; 2008 Aug; 34(8):789-95. PubMed ID: 18608462
[TBL] [Abstract][Full Text] [Related]
5. Reversal of resistance against doxorubicin by a newly developed compound, oxalyl bis(N-phenyl)hydroxamic acid in vitro.
Choudhuri SK; Chatterjee A
Anticancer Drugs; 1998 Oct; 9(9):825-32. PubMed ID: 9840730
[TBL] [Abstract][Full Text] [Related]
6. Antarth, a polyherbal preparation protects against the doxorubicin-induced toxicity without compromising its Antineoplastic activity.
Jagetia GC; Reddy TK; Malagi KJ; Nayak BS; Naidu MB; Ravikiran PB; Kamath SU; Shetty PC; Reddy DS
Phytother Res; 2005 Sep; 19(9):772-8. PubMed ID: 16220569
[TBL] [Abstract][Full Text] [Related]
7. Effects of L-histidinol on the antitumour activity and acute cardiotoxicity of doxorubicin in mice.
Al-Shabanah OA; Badary OA; Al-Gharably NM; Al-Sawaf HA
Pharmacol Res; 1998 Sep; 38(3):225-30. PubMed ID: 9782074
[TBL] [Abstract][Full Text] [Related]
8. Boswellic acids synergize antitumor activity and protect against the cardiotoxicity of doxorubicin in mice bearing Ehrlich's carcinoma.
Ali SA; Zaitone SA; Moustafa YM
Can J Physiol Pharmacol; 2015 Aug; 93(8):695-708. PubMed ID: 26230640
[TBL] [Abstract][Full Text] [Related]
9. Enhanced antitumour activity of doxorubicin and simvastatin combination loaded nanoemulsion treatment against a Swiss albino mouse model of Ehrlich ascites carcinoma.
Alkreathy HM; Alkhatib MH; Al Musaddi SA; Balamash KSA; Osman NN; Ahmad A
Clin Exp Pharmacol Physiol; 2019 May; 46(5):496-505. PubMed ID: 30724380
[TBL] [Abstract][Full Text] [Related]
10. Enhanced anticancer effect and reduced toxicity of doxorubicin in combination with thymoquinone released from poly-N-acetyl glucosamine nanomatrix in mice bearing solid Ehrlish carcinoma.
El-Ashmawy NE; Khedr EG; Ebeid EM; Salem ML; Zidan AA; Mosalam EM
Eur J Pharm Sci; 2017 Nov; 109():525-532. PubMed ID: 28890201
[TBL] [Abstract][Full Text] [Related]
11. Effect of dihydrokainate on the antitumor activity of doxorubicin.
Sadzuka Y; Yamashita Y; Sugiyama T; Sonobe T
Cancer Lett; 2002 May; 179(2):157-63. PubMed ID: 11888670
[TBL] [Abstract][Full Text] [Related]
12. Iron N-(2-hydroxy acetophenone) glycinate (FeNG), a non-toxic glutathione depletor circumvents doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo.
Ganguly A; Chakraborty P; Banerjee K; Chatterjee S; Basu S; Sarkar A; Chatterjee M; Choudhuri SK
Biometals; 2012 Feb; 25(1):149-63. PubMed ID: 21915630
[TBL] [Abstract][Full Text] [Related]
13. The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo.
Majumder S; Dutta P; Mookerjee A; Choudhuri SK
Chem Biol Interact; 2006 Feb; 159(2):90-103. PubMed ID: 16289015
[TBL] [Abstract][Full Text] [Related]
14. The antitumor effects of tetrodotoxin and/or doxorubicin on Ehrlich ascites carcinoma-bearing female mice.
El-Dayem SM; Fouda FM; Ali EH; Motelp BA
Toxicol Ind Health; 2013 Jun; 29(5):404-17. PubMed ID: 22317827
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effect of probimane on anticancer cytotoxicity of doxorubicin in vitro.
Zhang Y; Ye QX; Liu J; Zhang ZY; Zhang TM
Zhongguo Yao Li Xue Bao; 1994 Jan; 15(1):56-9. PubMed ID: 8010087
[TBL] [Abstract][Full Text] [Related]
16. Modulatory effects of melatonin and vitamin E on doxorubicin-induced cardiotoxicity in Ehrlich ascites carcinoma-bearing mice.
Wahab MH; Akoul ES; Abdel-Aziz AA
Tumori; 2000; 86(2):157-62. PubMed ID: 10855855
[TBL] [Abstract][Full Text] [Related]
17. A novel copper complex induces ROS generation in doxorubicin resistant Ehrlich ascitis carcinoma cells and increases activity of antioxidant enzymes in vital organs in vivo.
Mookerjee A; Basu JM; Majumder S; Chatterjee S; Panda GS; Dutta P; Pal S; Mukherjee P; Efferth T; Roy S; Choudhuri SK
BMC Cancer; 2006 Nov; 6():267. PubMed ID: 17107616
[TBL] [Abstract][Full Text] [Related]
18. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
[TBL] [Abstract][Full Text] [Related]
19. The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor.
Friche E; Jensen PB; Sehested M; Demant EJ; Nissen NN
Cancer Commun; 1990; 2(9):297-303. PubMed ID: 1976341
[TBL] [Abstract][Full Text] [Related]
20.
Qu X; Zhai J; Hu T; Gao H; Tao L; Zhang Y; Song Y; Zhang S
Xenobiotica; 2019 Sep; 49(9):1116-1125. PubMed ID: 29985077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
